Status:
TERMINATED
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disea...
Eligibility Criteria
Inclusion
- Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer
- Progression on or after endocrine treatment
- Measureable disease as per RECIST
- ECOG 0, 1 or 2
Exclusion
- Evidence of CNS or leptomeningeal metastases
- Previous treatment with fulvestrant
- Previous chemotherapy for locally advanced or metastatic breast cancer
- Cirrhosis or chronic active/persistent hepatitis
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT01528345
Start Date
April 1 2012
End Date
April 1 2015
Last Update
July 11 2016
Active Locations (67)
Enter a location and click search to find clinical trials sorted by distance.
1
Ironwood Cancer and Research Centers SC
Chandler, Arizona, United States, 85224
2
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas, United States, 72703
3
City of Hope National Medical Center COH 3
Duarte, California, United States, 91010-3000
4
University of California San Diego - Moores Cancer Center Moores UCSD Cancer Ctr. SC-1
La Jolla, California, United States, 92093-0658